Return on Equity (ROE)
since 2018
Calculation
Moderna Inc., ROE, long-term trends, calculation
| ROE | = | 100 | × | Net income (loss)1 | ÷ | Stockholders’ equity1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2022 | 43.73% | = | 100 | × | 8,362) | ÷ | 19,123) |
| Dec 31, 2021 | 86.26% | = | 100 | × | 12,202) | ÷ | 14,145) |
| Dec 31, 2020 | -29.17% | = | 100 | × | (747) | ÷ | 2,561) |
| Dec 31, 2019 | -43.75% | = | 100 | × | (514) | ÷ | 1,175) |
| Dec 31, 2018 | -25.14% | = | 100 | × | (385) | ÷ | 1,530) |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 US$ in millions
Comparison to Competitors
Moderna Inc., ROE, long-term trends, comparison to competitors
| Moderna Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Zoetis Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2022 | 43.73% | 68.60% | 178.97% | 20.37% | 14.39% | 58.64% | 21.62% | 23.36% | 31.57% | 32.79% | 19.14% | 15.80% | 47.99% |
| Dec 31, 2021 | 86.26% | 74.91% | 87.96% | 19.46% | 14.24% | 62.16% | 29.55% | 28.20% | 34.17% | 28.47% | 43.03% | 18.94% | 44.84% |
| Dec 31, 2020 | -29.17% | 35.30% | 77.20% | -23.84% | 9.17% | 109.79% | 0.68% | 23.25% | 27.91% | 15.21% | 31.86% | 18.47% | 43.46% |
| Dec 31, 2019 | -43.75% | — | 81.07% | 6.66% | 9.94% | 319.09% | 23.91% | 25.42% | 37.99% | 25.77% | 19.08% | 12.45% | 55.39% |
| Dec 31, 2018 | -25.14% | — | 67.15% | 35.07% | 9.40% | 32.88% | 25.51% | 25.60% | 23.30% | 17.59% | 27.91% | 10.65% | 65.35% |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Moderna Inc., ROE, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Moderna Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2022 | 43.73% | 28.34% |
| Dec 31, 2021 | 86.26% | 30.10% |
| Dec 31, 2020 | -29.17% | 17.15% |
| Dec 31, 2019 | -43.75% | 28.09% |
| Dec 31, 2018 | -25.14% | 26.26% |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Industry (Health Care)
Moderna Inc., ROE, long-term trends, comparison to industry (health care)
| Moderna Inc. | Health Care | |
|---|---|---|
| Dec 31, 2022 | 43.73% | 22.52% |
| Dec 31, 2021 | 86.26% | 23.00% |
| Dec 31, 2020 | -29.17% | 16.14% |
| Dec 31, 2019 | -43.75% | 21.17% |
| Dec 31, 2018 | -25.14% | 17.64% |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).